Prognostic impact of the acute reactiveness to intravenous administration of tolvaptan sodium phosphate in patients with acute decompensated heart failure.

ABSTRACT:

Aims

Intravenous tolvaptan sodium phosphate (IV-tolvaptan) is a novel aquaretic agent for acute decompensated heart failure (ADHF). This study evaluated its short-term effects and prognostic implications in clinical practice.

Methods and results

In this retrospective cohort of 169 consecutive ADHF patients receiving IV-tolvaptan for the first time (mean age 76.0 ± 12.7 years; 50.9% female), we measured hourly urine output over 6 h and assessed clinical and biochemical parameters at baseline and 24 h post-dose. The primary endpoint was a composite of all-cause mortality and heart failure rehospitalization. At 24 h, IV-tolvaptan significantly reduced body weight (mean difference: -1.1 ± 2.3 kg, P < 0.001), NT-proBNP (median change: -1704 pg/mL; P < 0.001), and ur

SUBMITTER: Ouchi S 

PROVIDER: S-EPMC12415332 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature